Email this article The effectiveness of the organization and specific prevention of Rh-conflict during pregnancy
- Authors: Kharkevich O.N.1, Dorovskaya E.N.1
-
Affiliations:
- Military Medical Academy
- Issue: Vol 42, No 2 (2023)
- Pages: 141-147
- Section: Original articles
- URL: https://journals.rcsi.science/RMMArep/article/view/316028
- DOI: https://doi.org/10.17816/rmmar312193
- ID: 316028
Cite item
Full Text
Abstract
AIM: The aim of the study was to evaluate the effectiveness of the organization and medical provision of complex specific antenatal and postpartum prevention of primary isoimmunization with domestic anti-Rh0(D) immunoglobulin in Rh-negative women.
MATERIALS AND METHODS: To achieve the goal, an algorithm for managing pregnancy in Rh-negative women was developed, complex antenatal and postpartum prophylaxis of primary isoimmunization with anti-Rh0(D) immunoglobulin was carried out, and its effectiveness was evaluated in 37 women who gave birth to Rh-positive newborns. If antibodies to the Rh0(D) antigen were not detected, then at 28 weeks pregnant women were administered human immunoglobulin anti-Rh0(D) at a dose of 1500 IU (300 μg). Anti-Rh0(D) antibody titer was monitored every 2–3 weeks before delivery. Mothers were re-introduced with human anti-Rh0(D) immunoglobulin at a dose of 1500 IU (300 μg) within 24–72 hours after the birth of an Rh-positive child. 6 months after delivery, the antibody titer to the Rh0(D) antigen was re-determined.
RESULTS: After the introduction of domestic human immunoglobulin anti-Rh0(D), side effects and allergic reactions were not registered. All 37 (100%) women were delivered at term, of which 7 (18.9%) were delivered abdominally. All newborns were born with an Apgar score of 8–9 without hemolytic disease. The titer of antibodies to the Rh0(D) antigen was negative in 24 (64.9%) women 6 months after delivery. 13 (35.1%) mothers had a post-vaccination antibody titer not higher than 1 : 2, which is allowed by the instructions for the anti-Rh0(D) human immunoglobulin preparation. They tested negative again 12 months after delivery.
CONCLUSION: The results of the study showed a rather high efficiency of the organization and medical provision of complex specific antenatal and postpartum prevention of primary isoimmunization with domestic anti-Rh0(D) immunoglobulin in Rh-negative women.
Full Text
##article.viewOnOriginalSite##About the authors
Ol'ga N. Kharkevich
Military Medical Academy
Author for correspondence.
Email: kharkevich.olga@mail.ru
ORCID iD: 0000-0002-1663-7263
SPIN-code: 7591-5730
Scopus Author ID: 37034214500
ResearcherId: U-2332-2017
M.D., D.Sc. (Medicine), Professor, Professor of the clinic (Department) of obstetrics and gynecology
Russian Federation, Saint PetersburgElena N. Dorovskaya
Military Medical Academy
Email: el.dorovskay@yandex.ru
SPIN-code: 1708-6513
ResearcherId: 1185485
M.D., Deputy Head (Pediatric Care) of the Obstetrics and Gynecology Clinic
Russian Federation, Saint PetersburgReferences
- Konoplyannikov AG, Pavlova NG. Isoserological incompatibility of maternal and fetal blood. Hemolytic disease of the fetus and newborn. In: Savel’eva GM, Sukhikh GT, Serov VN, Radzinskiy VE, eds. Obstetrics. National leadership. 2nd edition, revised and enlarged. Moscow: GETAR-Media Publ.; 2015. P. 324–334. (In Russ.)
- Konoplyannikov AG, Tetruashvili NK, Mikhailov AV, et al. Rh isoimmunization. Hemolytic disease of the fetus: clinical guidelines. Moscow: Ministry of Health of the Russian Federation Publishing House; 2020. 45 p. (In Russ.)
- Cunningham FG, Leveno KJ, Bloom SL, et al. Williams Obstetrics. 25th edition. McGraw-Hill Education/Medical; 2018. 1344 р.
- Moise KJ Jr. Management of rhesus all immunization in pregnancy. Obstet Gynecol. 2008;112(1):164–176.
- Kharkevich ON, Gerasimovich SA. Modern prenatal technologies to reduce reproductive losses in fetal hemolytic disease. ARS medika. 2012;(5):104–110. (In Russ.)
- White J, Qureshi H, Massey E, et al. British Committee for Standards in Hematology. Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med. 2016;26(4):246–263. doi: 10.1111/tme.12299
- McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane database Syst Rev 2015;2015(9): CD000020. doi: 10.1002/14651858.CD000020.pub3
- Eklund J. Prevention of Rh immunization in Finland. A national study, 1969–1977. Acta Paediatr Scand Suppl. 1978(274):1–57.
- Bartch F, Kjellman H. Postpartum prophylaxis with 250 µg of anti-D. In: Kabi Scientific report. No. 79 99 023. Stockholm; 1979. Р. 112–123.
- Hermann M, Kjellman H, Ljunggren C. Antenatal prophylaxis of Rh immunization with 250 micrograms anti-D immunoglobulin. Acta Obstet. Gynecol. Scand. Suppl. 1984;124:1–15. doi: 10.3109/00016348409157011
- Qureshi H, Massey E, Kirwan D, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of hemolytic disease of the fetus and newborn. Transfus Med. 2014;24(1):8–20. doi: 10.1111/tme.12091
- Bennardello F, Coluzzi S, Curciarello G, et al. Recommendations for the prevention and treatment of hemolytic disease of the fetus and newborn. Blood Transfus. 2015;13(1):109–134. doi: 10.2450/2014.0119-14
- Ozherel’eva MA, Kravchenko EN, Vetrov VV, et al. Prevention of hemolytic disease of the fetus and newborn and its severe forms in Rh-conflict (literature review). Detskaya meditsina Severo-Zapada. 2015;6(3):42–48. (In Russ.)
- Konoplyannikov AG, Sichinava LG, Latyshkevich OA, et al. Past, present and future of immunoprophylaxis of hemolytic disease of the fetus and newborn. StatusPraesens. Ginekologiya, akusherstvo, besplodny brak. 2019(2(55)):109–115. (In Russ.)
- Ermolova NV, Petrov YuA, Kosenko LB. Prevention of hemolytic disease in the fetus and newborn. Glavny vrach Yuga Rossii. 2022(2(83)):14–16. (In Russ.)
Supplementary files
